DWS ESG Biotech LC
DE0009769976
DWS ESG Biotech LC/ DE0009769976 /
NAV10/05/2024 |
Chg.-4.7900 |
Type de rendement |
Focus sur l'investissement |
Société de fonds |
280.5500EUR |
-1.68% |
reinvestment |
Equity
Worldwide
|
DWS Investment GmbH ▶ |
Stratégie d'investissement
The fund is actively managed. The fund is not managed in reference to a benchmark. The fund promotes environmental and social characteristics and is subject to the disclosure requirements of a financial product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. More ESG information is available in the sales prospectus and on the DWS website. The objective of the investment policy is to achieve sustained capital appreciation that exceeds the benchmark (No benchmark).
To achieve this, the fund invests mainly in equities of international companies whose revenues or earnings, as reported in the most recent annual report or other suitable documents of the company, were generated primarily from the biotechnology sector, or whose expenditure was primarily on this sector. Equities of issuers from the health care sector may also be added. When selecting the suitable investments, environmental and social aspects as well as the principles of corporate governance ("ESG standards") are of key importance for the implementation of the fund"s sustainable investment strategy.
Objectif d'investissement
The fund is actively managed. The fund is not managed in reference to a benchmark. The fund promotes environmental and social characteristics and is subject to the disclosure requirements of a financial product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. More ESG information is available in the sales prospectus and on the DWS website. The objective of the investment policy is to achieve sustained capital appreciation that exceeds the benchmark (No benchmark).
Opérations
Type de rendement: |
reinvestment |
Fonds Catégorie: |
Equity |
Région de placement: |
Worldwide |
Branche: |
Sector Biotechnology |
Benchmark: |
- |
Début de l'exercice: |
01/10 |
Dernière distribution: |
02/01/2018 |
Banque dépositaire: |
State Street Bank International GmbH |
Domicile: |
Germany |
Permission de distribution: |
Austria, Germany |
Gestionnaire du fonds: |
Dr. Noushin Irani |
Actif net: |
364.61 Mio.
EUR
|
Date de lancement: |
16/08/1999 |
Focus de l'investissement: |
- |
Conditions
Surtaxe d'émission: |
5.00% |
Frais d'administration max.: |
1.30% |
Investissement minimum: |
0.00 EUR |
Deposit fees: |
- |
Frais de rachat: |
0.00% |
Prospectus simplifié: |
Télécharger (Version imprimée) |
Société de fonds
Société de fonds: |
DWS Investment GmbH |
Adresse: |
Mainzer Landstraße 11-17, 60329, Frankfurt am Main |
Pays: |
Germany |
Internet: |
www.dws.de
|
Actifs
Stocks |
|
93.90% |
Money Market |
|
3.10% |
Cash |
|
3.00% |
Pays
United States of America |
|
82.10% |
Netherlands |
|
4.10% |
Denmark |
|
3.20% |
Germany |
|
1.80% |
United Kingdom |
|
0.70% |
Ireland |
|
0.60% |
Virgin Islands (British) |
|
0.50% |
Canada |
|
0.40% |
Sweden |
|
0.30% |
Switzerland |
|
0.20% |
Autres |
|
6.10% |
Branches
Pharma/Biotechnology |
|
89.70% |
Pharma, production |
|
4.30% |
Autres |
|
6.00% |